$1.74 Billion is the total value of Cormorant Asset Management, LP's 72 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Sell | SPDR SERIES TRUSTput | $78,939,000 | -5.7% | 900,000 | -2.7% | 4.53% | -19.9% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $75,161,000 | +7.1% | 2,966,108 | -17.6% | 4.32% | -9.0% |
| AXNX | Sell | AXONICS MODULATION TECH INC | $51,315,000 | +68.4% | 1,252,495 | -1.6% | 2.95% | +43.1% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $46,060,000 | -34.8% | 400,000 | -33.3% | 2.65% | -44.6% |
| PRNB | Sell | PRINCIPIA BIOPHARMA INC | $45,201,000 | -5.8% | 1,361,898 | -3.5% | 2.60% | -20.0% |
| ANAB | Sell | ANAPTYSBIO INC | $39,494,000 | -41.2% | 700,000 | -23.9% | 2.27% | -50.1% |
| QTNT | Sell | QUOTIENT LTD | $35,530,000 | -14.3% | 3,800,000 | -17.4% | 2.04% | -27.1% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $34,189,000 | -4.4% | 225,000 | -25.0% | 1.96% | -18.7% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $33,016,000 | -8.3% | 350,000 | -22.2% | 1.90% | -22.1% |
| CRSP | Sell | CRISPR THERAPEUTICS AGnamen akt | $32,970,000 | +2.6% | 700,000 | -22.2% | 1.89% | -12.8% |
| ALLK | Sell | ALLAKOS INC | $28,165,000 | -7.3% | 650,000 | -13.3% | 1.62% | -21.2% |
| MYOK | Sell | MYOKARDIA INC | $25,070,000 | -19.6% | 500,000 | -16.7% | 1.44% | -31.7% |
| GLPG | Sell | GALAPAGOS NVspon adr | $22,576,000 | -35.4% | 175,000 | -41.7% | 1.30% | -45.1% |
| CCXI | Sell | CHEMOCENTRYX INC | $21,997,000 | -37.3% | 2,365,280 | -6.4% | 1.26% | -46.7% |
| ARGX | Sell | ARGENX SEsponsored adr | $21,237,000 | -38.1% | 150,000 | -45.5% | 1.22% | -47.4% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $20,849,000 | +71.0% | 450,000 | -10.0% | 1.20% | +45.4% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $18,309,000 | -11.5% | 100,000 | -23.1% | 1.05% | -24.7% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $15,616,000 | -9.4% | 1,271,685 | -0.0% | 0.90% | -23.0% |
| GOSS | Sell | GOSSAMER BIO INC | $14,265,000 | +0.8% | 643,129 | -1.5% | 0.82% | -14.4% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $14,232,000 | -15.3% | 400,000 | -20.0% | 0.82% | -28.0% |
| INSP | Sell | INSPIRE MED SYS INC | $12,130,000 | -14.5% | 200,000 | -20.0% | 0.70% | -27.3% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $11,726,000 | +4.6% | 200,000 | -20.0% | 0.67% | -11.0% |
| AUTL | Sell | AUTOLUS THERAPEUTICS PLCspon ads | $11,270,000 | -57.9% | 700,000 | -17.6% | 0.65% | -64.2% |
| RARX | Sell | RA PHARMACEUTICALS INC | $10,525,000 | +17.5% | 350,000 | -12.5% | 0.60% | -0.2% |
| ZLAB | Sell | ZAI LAB LTDadr | $10,461,000 | +1.3% | 300,000 | -14.3% | 0.60% | -13.9% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $9,695,000 | -22.2% | 500,000 | -16.7% | 0.56% | -33.8% |
| RUBY | Sell | RUBIUS THERAPEUTICS INC | $9,438,000 | -19.8% | 600,000 | -7.7% | 0.54% | -31.8% |
| HARP | Sell | HARPOON THERAPEUTICS INC | $8,450,000 | +32.4% | 649,994 | -3.5% | 0.48% | +12.5% |
| ATRA | Sell | ATARA BIOTHERAPEUTICS INC | $8,044,000 | -63.2% | 400,000 | -27.3% | 0.46% | -68.7% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $7,466,000 | -67.6% | 968,294 | -25.5% | 0.43% | -72.5% |
| GNFT | Sell | GENFIT S Aads | $6,314,000 | -24.8% | 319,700 | -8.7% | 0.36% | -36.1% |
| DTIL | Sell | PRECISION BIOSCIENCES, INC - SERIES B PREFERRED | $6,195,000 | -55.8% | 467,518 | -40.1% | 0.36% | -62.4% |
| IFRX | Sell | INFLARX NV | $4,740,000 | -95.2% | 1,500,000 | -42.1% | 0.27% | -95.9% |
| AVRO | Sell | AVROBIO INC | $4,472,000 | -32.4% | 275,000 | -8.3% | 0.26% | -42.5% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $4,222,000 | -46.8% | 50,000 | -44.4% | 0.24% | -54.7% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $2,840,000 | -27.2% | 75,000 | -25.0% | 0.16% | -38.3% |
| ITRM | Sell | ITERUM THERAPEUTICS PLC | $2,727,000 | -14.7% | 396,385 | -0.5% | 0.16% | -27.3% |
| SRRK | Sell | SCHOLAR ROCK HLDG CORP | $2,379,000 | -29.2% | 150,000 | -16.2% | 0.14% | -39.6% |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $1,673,000 | -43.2% | 350,000 | -12.5% | 0.10% | -51.8% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $548,000 | -78.2% | 250,000 | -40.6% | 0.03% | -81.8% |
| SLDB | Exit | SOLID BIOSCIENCES INC | $0 | – | -250,000 | -100.0% | -0.16% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -30,000 | -100.0% | -0.17% | – |
| COLL | Exit | COLLEGIUM PHARMACEUTICAL INC | $0 | – | -200,000 | -100.0% | -0.20% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.25% | – |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -454,549 | -100.0% | -0.31% | – |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -270,000 | -100.0% | -0.33% | – |
| MYOV | Exit | MYOVANT SCIENCES LTD | $0 | – | -650,000 | -100.0% | -1.05% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -450,000 | -100.0% | -1.67% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.